Clinical-stage biotech firm Arcellx's Q3 revenue drops, misses expectations

Arcellx

05/11/2025 21:10

Overview

Arcellx Q3 revenue falls sharply, missing analysts' expectations

However, Adjusted EPS beats analyst expectations despite increased G&A expenses

Net loss comes in lower than analysts' estimates

Outlook

Company expects cash reserves to fund operations into 2028

Result Drivers

COLLABORATION REVENUE DECLINE - Revenue decreased due to completion of dosing and manufacturing in iMMagine-1 trial

R&D EXPENSES DROP - Decrease in R&D expenses attributed to completion of dosing and manufacturing in iMMagine-1 trial

INCREASED G&A COSTS - Rise in G&A expenses due to higher commercial readiness and personnel costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$4.95 mln
$10.19 mln (16 Analysts)
Q3 EPS
Beat
-$0.99
-$1.06 (18 Analysts)
Q3 Net Income
Beat
-$55.78 mln
-$57.33 mln (13 Analysts)
Q3 Operating Income
Beat
-$61.78 mln
-$62.50 mln (13 Analysts)
Q3 Pretax Profit
Beat
-$55.78 mln
-$56.96 mln (12 Analysts)
Q3 Operating Expenses
$66.73 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arcellx Inc is $112.50, about 21.6% above its November 4 closing price of $88.18

Press Release: ID:nBw9sdsT0a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)